[Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives?]
Résumé
What is an innovative therapeutics for the Alzheimer's disease? An already used therapeutics which appeals to a recent and innovative concept or a therapeutic still putative based on tracks turned out experimentally but which still ask to be supported by man? Some therapeutic used at present are based on often former observations (anti-acetylcholinesterasic strategy) or more recent (antiglutamatergic strategy) but cannot be really considered as therapeutic innovative. They will be reviewed thus quickly because treated somewhere else. Potentially innovative therapeutics arise from recent headways and are there often only because of their stammerings. If the biology of Tau proteins is well-known, its therapeutic approach is little developed. On the contrary, therapeutics approaches turns essentially around the peptide amyloid, whether its training or the cellular consequences of its overproduction. This article is centred on the various therapeutic approaches which we can prospectively propose and which are very promising for some and for the others, collide with abstract or theoretical problems which will be approached here.